Cargando…
Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. J. Pers. Med. 2023, 13, 553
Autores principales: | Graziosi, Luigina, Natalizi, Nicola, Donini, Annibale |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303780/ https://www.ncbi.nlm.nih.gov/pubmed/37373963 http://dx.doi.org/10.3390/jpm13060974 |
Ejemplares similares
-
Reply to Graziosi et al. Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on “Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. J. Pers. Med. 2023, 13, 553”
por: Chen, Yi-Fu, et al.
Publicado: (2023) -
Evaluation of peritoneal Carcinoembryonic Antigen as a survival prognostic factor in gastric cancer patients: a single western center experience
por: Natalizi, Nicola, et al.
Publicado: (2023) -
Prognostic Survival Significance of Signet Ring Cell (SRC) Gastric Cancer: Retrospective Analysis from a Single Western Center
por: Graziosi, Luigina, et al.
Publicado: (2023) -
Is Adjuvant Chemotherapy Beneficial to All Patients With pT3N0M0 Stage Gastric Cancer?
por: Huang, Jiao-Bao, et al.
Publicado: (2021) -
Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy
por: Shao, Xinxin, et al.
Publicado: (2023)